Dual wavelength-triggered gold nanorods for anticancer treatment

1Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Gold nanomaterials with light-responsive properties can be exploited as light-triggered delivery vehicles to enhance the therapeutic efficacy of anticancer drugs. Additionally, different wavelengths of light can be utilized to achieve the combined effects of light-triggered release of therapeutics and light-induced localized heating, which results in improved anticancer efficacy. Herein, we describe methods to develop gold nanorod (AuNR) complexes that provide drug delivery or photothermal therapy when activated by ultraviolet (UV) or near-infrared (NIR) wavelengths of light, respectively. The surface functionalization of AuNRs with three key components is presented. The first component, cyclodextrin, serves to encapsulate drugs of interest. The second component, dextran-phenyl-azo-benzoic acid (DexAzo), serves as a capping agent that undergoes a conformational change upon UV light activation to expose the drugs for release. The third component is a folic acid-based targeting ligand that provides efficient delivery of the AuNR complexes to cancer cells. The dual wavelength activation of these drug-loaded AuNR complexes, which enables one to achieve highly efficient anticancer therapy through the combined effects of UV-triggered drug release and NIR-induced hyperthermia, is also described.

Cite

CITATION STYLE

APA

Pacardo, D. B., Ligler, F. S., & Gu, Z. (2017). Dual wavelength-triggered gold nanorods for anticancer treatment. In Methods in Molecular Biology (Vol. 1570, pp. 195–208). Humana Press Inc. https://doi.org/10.1007/978-1-4939-6840-4_13

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free